- Home
- CHRS vs CLYM Comparison
CHRS vs CLYM Comparison
Compare CHRS & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CLYM
- Stock Information
- Founded
- CHRS 2010
- CLYM 2018
- Country
- CHRS United States
- CLYM United States
- Employees
- CHRS N/A
- CLYM N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CLYM
- Sector
- CHRS Health Care
- CLYM
- Exchange
- CHRS Nasdaq
- CLYM NYSE
- Market Cap
- CHRS 102.0M
- CLYM 83.8M
- IPO Year
- CHRS 2014
- CLYM 2021
- Fundamental
- Price
- CHRS $1.04
- CLYM $1.45
- Analyst Decision
- CHRS Buy
- CLYM Buy
- Analyst Count
- CHRS 3
- CLYM 1
- Target Price
- CHRS $4.68
- CLYM $10.00
- AVG Volume (30 Days)
- CHRS 1.3M
- CLYM 357.1K
- Earning Date
- CHRS 08-07-2025
- CLYM 08-13-2025
- Dividend Yield
- CHRS N/A
- CLYM N/A
- EPS Growth
- CHRS N/A
- CLYM N/A
- EPS
- CHRS N/A
- CLYM N/A
- Revenue
- CHRS $272,251,000.00
- CLYM N/A
- Revenue This Year
- CHRS N/A
- CLYM N/A
- Revenue Next Year
- CHRS $99.43
- CLYM N/A
- P/E Ratio
- CHRS $2.44
- CLYM N/A
- Revenue Growth
- CHRS 19.87
- CLYM N/A
- 52 Week Low
- CHRS $0.66
- CLYM $1.05
- 52 Week High
- CHRS $2.43
- CLYM $9.05
- Technical
- Relative Strength Index (RSI)
- CHRS 68.96
- CLYM N/A
- Support Level
- CHRS $0.88
- CLYM N/A
- Resistance Level
- CHRS $1.06
- CLYM N/A
- Average True Range (ATR)
- CHRS 0.07
- CLYM 0.00
- MACD
- CHRS 0.02
- CLYM 0.00
- Stochastic Oscillator
- CHRS 93.38
- CLYM 0.00
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.